Safe Group announces half-year sales of €2.75 million, 27% growth

Direct sales revenue of €1.183M in Q2 2022, up +59% compared to Q1 2022 Doubling of Sycamore and Hickory users Fully integrated production of SteriSpineTM  technologies within the group Eragny-sur-Oise, Fleurieux sur l'Arbresle, France, July 7th , 2022 5:45pm CET –  Safe (FR0013467123 – ALSAF), a company specializing in the design, manufacturing and marketing of single-use technologies for spinal surgeries, delivering the safest treatment for spinal fractures urgently treated, announces its half-yearly revenues for the period ending June 30, 2022. "Safe Group closes the first half of 2022 with an overall half-year sales growth of 27% compared to the first half of 2021 driven by Safe Orthopaedics (+46%) and Safe Medical (+26%) direct sales growth, while indirect sales are still limited by the health situation and the financial conditions of our distributors (+1%),"  commented Pierre Dumouchel, Safe Group's Chairman and CEO. "In the second quarter, all of our Safe Orthopaedics direct sales forces posted double-digit growth, accelerated by the promotion of Sycamore and Hickory, even though marketing and sales headcount was held back by a third. Safe Medical continues to show steady growth of 26%." S1 2022 revenues Thousands euros Q1 2022 Q2 2022 S1 2022 Q1 2021 Q2 2021 S1 2021 Variation Q2 22/ Q2 21 Variation S1 22/ S1 21 Direct Sales (FR, All, R-U, USA) 585 598 1 183 437 375 811 +59% +46% Indirect Sales 343 219 562 258 298 556 Full story available on Benzinga.com